Meeder Asset Management Inc Revance Therapeutics, Inc. Transaction History

Meeder Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 09, 2021	SELL	$23.41 - $28.34 $122,691 - $148,529	-5,241 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$23.23 - $34.3 $121,748 - $179,766	5,241 New	5,241 $130,000
Q2 2020 Aug 11, 2020	SELL	$12.6 - $26.55 $34,007 - $71,658	-2,699 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$12.46 - $27.81 $13,406 - $29,923	1,076 Added 66.3%	2,699 $41,000
Q4 2019 Feb 13, 2020	BUY	$11.66 - $20.15 $6,762 - $11,687	580 Added 55.61%	1,623 $26,000
Q3 2019 Oct 17, 2019	BUY	$10.22 - $14.5 $10,659 - $15,123	1,043 New	1,043 $14,000
Q1 2019 Apr 16, 2019	SELL	$15.4 - $20.39 $9,455 - $12,519	-614 Closed	0 $0
Q4 2018 Jan 17, 2019	BUY	$18.06 - $24.96 $11,088 - $15,325	614 New	614 $12,000
Q1 2018 May 03, 2018	SELL	$29.15 - $37.4 $3,702 - $4,749	-127 Closed	0 $0
Q4 2017 Feb 02, 2018	BUY	$24.55 - $36.3 $3,117 - $4,610	127	127 $5,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.